SCHEMBL5756893

SCHEMBL5756893

Cc1ccc(C(=O)NCCC2=CCCCC2)c(=O)n1-c1cccc(C#N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
TP53 P04637 1/20 0.48
ALDH1A1 P00352 11/20 0.47
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 2/20 0.47
HSD17B10 Q99714 2/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
ATM Q13315 1/20 0.47
KDM4E B2RXH2 4/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756289 0.85 ELANE (0.58) MAPTTP53ALDH1A1RAB9ANPC1
SCHEMBL5756977 0.83 TP53 (0.47) MAPTTP53ALDH1A1RAB9ANPC1
SCHEMBL27643772 0.83 KLKB1 (0.48) MAPTTP53ALDH1A1RAB9ASMN1; SMN2
SCHEMBL5757207 0.82 ELANE (0.45) TP53RAB9ANPC1GAA
SCHEMBL5757117 0.82 ELANE (0.47) TP53ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL5756759 0.82 CNR1 (0.47) MAPTTP53RAB9ANPC1KMT2A
SCHEMBL5756339 0.80 LMNA (0.50) MAPTTP53ALDH1A1SMN1; SMN2HPGD
SCHEMBL5758327 0.79 CNR2 (0.44) ALDH1A1RAB9ANPC1SMN1; SMN2HTT
SCHEMBL5757078 0.79 NPC1 (0.44) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL5757706 0.79 ELANE (0.45) TP53ALDH1A1RAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 MAPT 1847/4885TP53 3353/4885ALDH1A1 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.